Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Solid Tumors, Adult
- Main trialPhase 1
- “This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.”In the company’s words, NCT06088472 on ClinicalTrials.gov
Other drugs for Solid Tumors, Adult
- PembrolizumabMerck & Co. · Phase 3
- EIK1001Eikon Therapeutics · Phase 2/3
- QL2107Qilu Pharmaceutical · Phase 3
- IFx-Hu2.0TuHURA Biosciences, Inc. · Phase 2/3
- FutibatinibTaiho · Phase 2/3
- MB11mAbxience Research S.L. · Phase 3
Coming up1
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 31 Dec 2027 | TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026